Ironwood Pharmaceuticals, Inc.
IRWD
$0.7267
-$0.0233-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 351.41M | 378.42M | 400.57M | 413.55M | 442.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.41M | 378.42M | 400.57M | 413.55M | 442.74M |
| Cost of Revenue | 7.55M | 26.77M | 29.73M | 19.12M | 6.15M |
| Gross Profit | 343.86M | 351.65M | 370.84M | 394.44M | 436.59M |
| SG&A Expenses | 143.87M | 157.25M | 153.48M | 148.50M | 142.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 255.29M | 282.66M | 281.85M | 266.26M | 246.80M |
| Operating Income | 96.12M | 95.76M | 118.72M | 147.30M | 195.94M |
| Income Before Tax | 65.20M | 71.56M | 86.13M | -1.01B | -948.07M |
| Income Tax Expenses | 64.32M | 74.68M | 78.94M | 72.46M | 83.49M |
| Earnings from Continuing Operations | 0.88 | -3.12 | 7.18 | -1.08K | -1.03K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 658.00K | 2.03M | 29.32M | 29.32M |
| Net Income | 880.00K | -2.46M | 9.21M | -1.05B | -1.00B |
| EBIT | 96.12M | 95.76M | 118.72M | 147.30M | 195.94M |
| EBITDA | 98.13M | 97.80M | 120.36M | 149.10M | 197.51M |
| EPS Basic | 0.01 | -0.02 | 0.06 | -6.77 | -6.45 |
| Normalized Basic EPS | 0.27 | 0.27 | 0.38 | 0.72 | 0.97 |
| EPS Diluted | 0.00 | -0.02 | 0.04 | -6.79 | -6.51 |
| Normalized Diluted EPS | 0.27 | 0.27 | 0.35 | 0.69 | 0.89 |
| Average Basic Shares Outstanding | 635.87M | 632.43M | 628.61M | 624.97M | 621.72M |
| Average Diluted Shares Outstanding | 636.40M | 632.96M | 659.62M | 655.97M | 684.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |